PENETREX Drug Patent Profile

When do Penetrex patents expire, and what generic alternatives are available?

Penetrex is a drug marketed by Sanofi Aventis Us and is included in one NDA.

The generic ingredient in PENETREX is enoxacin. There are three drug master file entries for this compound. Additional details are available on the enoxacin profile page.

Summary for PENETREX

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	105
Patent Applications:	4,693
DailyMed Link:	PENETREX at DailyMed

US Patents and Regulatory Information for PENETREX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sanofi Aventis Us	PENETREX	enoxacin	TABLET;ORAL	019616-004	Dec 31, 1991		DISCN	No	No
Sanofi Aventis Us	PENETREX	enoxacin	TABLET;ORAL	019616-005	Dec 31, 1991		DISCN	No	No

Expired US Patents for PENETREX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sanofi Aventis Us	PENETREX	enoxacin	TABLET;ORAL	019616-005	Dec 31, 1991
Sanofi Aventis Us	PENETREX	enoxacin	TABLET;ORAL	019616-004	Dec 31, 1991
Sanofi Aventis Us	PENETREX	enoxacin	TABLET;ORAL	019616-005	Dec 31, 1991
Sanofi Aventis Us	PENETREX	enoxacin	TABLET;ORAL	019616-005	Dec 31, 1991

International Patents for PENETREX

See the table below for patents covering PENETREX around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	1216292	DERIVES SESQUIHYDRATE DE NAPHTHTRINE, ET LEUR PREPARATION (SESQUIHYDRATE OF NAPHTHYRIDINE DERIVATIVES, AND PROCESS FOR THE PREPARATION THEREOF)
European Patent Office	0009425	NOVEL NAPHTYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
Finland	820466
South Korea	870000322

Supplementary Protection Certificates for PENETREX

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2344130	1790031-7	Sweden		PRODUCT NAME: OZENOXACIN; NAT. REG. NO/DATE: 54608 20170622; FIRST REG.: BE ES/H/414/01/DC 20170519
2344130	C201730036	Spain		PRODUCT NAME: OZENOXACINO; NATIONAL AUTHORISATION NUMBER: 82357-ES/H/0414/001/DC; DATE OF AUTHORISATION: 20170830; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): ES/H/414/01/DC; DATE OF FIRST AUTHORISATION IN EEA: 20170519
2344130	300884	Netherlands		PRODUCT NAME: OZENOXACIN; REGISTRATION NO/DATE: ES/H/414/1/DC 20170519
2344130	132017000093887	Italy		PRODUCT NAME: OZENOXACIN(DUBINE); AUTHORISATION NUMBER(S) AND DATE(S): ES/H/414/01/DC, 20170519;045237017, 20170711

PENETREX Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Penetrex

Introduction to Penetrex

Penetrex is a brand that encompasses two distinct products: a joint and muscle therapy cream, and an antibiotic known as enoxacin. This article will focus on the market dynamics and financial trajectory of the Penetrex joint and muscle therapy cream, as it is the more commercially prominent and widely recognized product in the consumer health market.

Market Position and Consumer Trust

Penetrex Joint & Muscle Therapy Cream has established itself as a trusted brand in the over-the-counter (OTC) market for joint and muscle relief. With over 2 million users, it is known for its proprietary blend of natural ingredients, including arnica, vitamin B6, and MSM, which penetrate deeply to alleviate discomfort[1].

Consumer Satisfaction and Market Leadership

The brand has strong consumer satisfaction and leadership on platforms like Amazon. This has been a key factor in its superior financial performance and growth. The brand's non-greasy, non-sticky, and non-staining formula, along with its cruelty-free and vegan status, has resonated well with consumers[1].

Financial Performance and Growth

Strategic Growth Initiatives

Wellbeam Consumer Health, the previous owner of the Penetrex brand, implemented several strategic growth initiatives that drove the brand's superior growth. This included leveraging deep industry knowledge and relationships with key industry participants to enhance the brand's market presence[5].

Sale to Carlin Consumer Health

In a significant move, Wellbeam Consumer Health sold Penetrex to Carlin Consumer Health, a company focused on acquiring OTC brands and backed by prominent investors such as Hildred Capital Management, Bourne Partners Strategic Capital, and The Emerson Group. This transaction was facilitated by Lincoln International and reflects the brand's strong financial performance and growth potential[5].

Market Dynamics

Competitive Landscape

The OTC market for joint and muscle relief is highly competitive, with numerous brands offering similar products. However, Penetrex has managed to differentiate itself through its unique blend of natural ingredients and its user-friendly, non-irritating formula. This differentiation has helped the brand maintain a strong market position despite the competition[1].

Consumer Preferences

Consumer preferences for natural, non-pharmacological solutions for joint and muscle pain have been on the rise. Penetrex has capitalized on this trend by offering a product that is free from harsh chemicals and is cruelty-free and vegan, aligning well with the values of many modern consumers[1].

Financial Trajectory

Revenue and Growth

The financial trajectory of Penetrex has been marked by consistent growth. The brand's strong performance on Amazon and other retail platforms has contributed significantly to its revenue. While the exact financial figures from the sale to Carlin Consumer Health were not disclosed, the transaction underscores the brand's financial health and potential for further growth[5].

Future Outlook

With the support of its new ownership, Penetrex is poised for continued growth. The brand is expected to expand its market reach through enhanced marketing strategies and possibly entering new markets. The financial backing from its investors will likely enable Penetrex to invest in research and development, further improving its product offerings and maintaining its competitive edge[5].

Impact of Ownership Change

Strategic Support

The acquisition by Carlin Consumer Health brings significant strategic support to the Penetrex brand. Carlin's focus on OTC brands and its infrastructure and capabilities are expected to drive superior value for Penetrex, enabling it to navigate the competitive landscape more effectively[5].

Market Expansion

The new ownership is likely to facilitate market expansion for Penetrex. With the financial and operational support from Carlin Consumer Health, the brand can explore new distribution channels, enhance its marketing efforts, and potentially enter international markets, further boosting its revenue and growth[5].

Key Takeaways

• Strong Consumer Trust: Penetrex has built a strong reputation among consumers for its effective joint and muscle relief.
• Market Leadership: The brand leads in consumer satisfaction and market presence, particularly on Amazon.
• Financial Growth: Penetrex has shown consistent financial growth, driven by its unique product offerings and strategic initiatives.
• New Ownership: The acquisition by Carlin Consumer Health is expected to support further growth and market expansion.
• Competitive Edge: Penetrex's natural ingredients and user-friendly formula differentiate it in a competitive market.

FAQs

What is Penetrex Joint & Muscle Therapy Cream used for?

Penetrex Joint & Muscle Therapy Cream is used for relieving joint and muscle discomfort. It is effective for various body parts such as the back, neck, knee, hand, and foot[1].

What are the key ingredients in Penetrex Joint & Muscle Therapy Cream?

The key ingredients include arnica, vitamin B6, and MSM, which work synergistically to penetrate deeply and alleviate discomfort[1].

Who is the current owner of the Penetrex brand?

The Penetrex brand is currently owned by Carlin Consumer Health, which acquired it from Wellbeam Consumer Health[5].

How has the ownership change impacted Penetrex?

The ownership change has brought strategic support and financial backing, which is expected to drive further growth and market expansion for the brand[5].

Is Penetrex suitable for all skin types?

Yes, Penetrex is non-greasy, non-sticky, and non-staining, making it suitable for most skin types. It is also cruelty-free and vegan[1].

Sources

1. Rite Aid: Penetrex Joint & Muscle Therapy Cream - 2 fl oz.
2. BioSpace: The Biopharma Patent Cliff: 9 Drugs Losing Exclusivity by the End of 2023.
3. PubMed: The economics of follow-on drug research and development.
4. RxList: Penetrex (Enoxacin): Side Effects, Uses, Dosage, Interactions.
5. Lincoln International: Wellbeam Consumer Health has sold Penetrex to Carlin Consumer Health.